Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy

Fig. 2

Cumulative incidence of drug-induced interstitial lung disease (DIILD) in cancer patients receiving subsequent antineoplastic therapy following prior immune checkpoint inhibitor-containing regimens. a Cumulative incidence of DIILD in the entire pan-cancer cohort. b Cumulative incidence of DIILD according to cancer type. c Cumulative incidence of DIILD in patients with lung cancer or other cancer types

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us